moatshark My

All holdings

Eli Lilly & Co

LLY

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
7
In their latest 13F (Q3 2026)
See who
Value held
$1.4bn
Combined value at quarter end
Last quarter
0 bought
7 sold or trimmed
Fund portfolios
3
Funds holding it
See which
Price at Q3 ’26 end
$1,155.58
-3.7% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

-12.9%Q4 ’24
+7.0%Q1 ’25
-5.6%Q2 ’25
-2.1%Q3 ’25
+40.8%Q4 ’25
-14.4%Q1 ’26
+30.4%Q2 ’26
-3.7%Q3 ’26
Q4 ’24: -12.9%; Q1 ’25: +7.0%; Q2 ’25: -5.6%; Q3 ’25: -2.1%; Q4 ’25: +40.8%; Q1 ’26: -14.4%; Q2 ’26: +30.4%; Q3 ’26: -3.7%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

4Q4 ’23
5Q1 ’24
5Q2 ’24
5Q3 ’24
5Q4 ’24
5Q1 ’25
7Q2 ’25
7Q3 ’25
7Q4 ’25
7Q1 ’26
7Q2 ’26
1Q3 ’26
Q4 ’23: 4; Q1 ’24: 5; Q2 ’24: 5; Q3 ’24: 5; Q4 ’24: 5; Q1 ’25: 5; Q2 ’25: 7; Q3 ’25: 7; Q4 ’25: 7; Q1 ’26: 7; Q2 ’26: 7; Q3 ’26: 1

Counts the managers on this site whose 13F for that quarter includes Eli Lilly & Co.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Eli Lilly & Co
Polen Capital Management6.9%$800m$800mTrimmed -27%12 qtrs
Jensen Investment Management4.5%$184m$184mTrimmed -33%5 qtrs
Mairs & Power3.5%$386m$386mTrimmed -1.3%53 qtrs
Horizon Kinetics0.1%$4.6m$4.6mTrimmed -3.6%13 qtrs
Dodge & Cox0.0%$49.5m$49.5mTrimmed -1.8%53 qtrs
Matrix Asset Advisors0.0%$352k$352kTrimmed -1.9%11 qtrs
Harris Associates (Oakmark)0.0%$517k$517kTrimmed -4.2%5 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Eli Lilly & Co
Bought or soldFiling
17 Aug 2026Jonsson PatrikEVP & President, LLY Int'l▼ Sold6,500$1175.10$7.6mForm 4
10 Aug 2026Zakrowski Donald ASVP, Finance, & CAO▼ Sold2,000$1185.01$2.4mForm 4
7 Aug 2026Hakim AnatEVP, GC & Secretary▼ Sold5,000$1190.00$6.0mForm 4

About the company

Sector
Health care · Pharmaceutical Preparations
Incorporated in
Indiana
Financial year ends
31 December
Shares outstanding
941m at 3 Aug 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$23bn2013
$20bn2015
$20bn2017
$22bn2019
$28bn2021
$34bn2023
$65bn2025
2013: $23bn; 2014: $20bn; 2015: $20bn; 2016: $18bn; 2017: $20bn; 2018: $21bn; 2019: $22bn; 2020: $25bn; 2021: $28bn; 2022: $29bn; 2023: $34bn; 2024: $45bn; 2025: $65bn
Eli Lilly & Co revenue and net income by year
YearRevenueNet income
2025$65bn$21bn
2024$45bn$11bn
2023$34bn$5.2bn
2022$29bn$6.2bn
2021$28bn$5.6bn
2020$25bn$6.2bn
2019$22bn$8.3bn
2018$21bn$3.2bn
2017$20bn−$204m
2016$18bn$2.7bn
2015$20bn$2.4bn
2014$20bn$2.4bn
2013$23bn$4.7bn

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.

In fund portfolios

US-registered funds run by these managers that hold Eli Lilly & Co, from their latest N-PORT filings.

Funds holding Eli Lilly & Co
Jensen Quality Growth FundJensen Investment Management5.5%$165m31 May 2026
Polen Global Growth FundPolen Capital Management4.7%$5.2m31 Jul 2026
Mairs & Power Growth FundMairs & Power3.0%$166m30 Jun 2026